US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immix Biopharma, Inc.

2.65

-0.0600-2.21%

Post-market: 2.650.00000.00%16:43 EDT

Volume:286.92K

Turnover:769.85K

Market Cap:73.81M

PE:-3.79

High:2.74

Open:2.70

Low:2.61

Close:2.71

Loading ...

Overview Company News Filings

Immix Biopharma announces ‘class-leading’ safety profile for NXC-201

Immix Biopharma Accelerates Toward BLA Submission for NEXICART-2, Paving Way for FDA Approval

Immix Biopharma Expands NEXICART-2 Clinical Trial Footprint, Accelerating Path to FDA Approval for Novel Cell Therapy

Immix Biopharma Announces Accelerated Nexicart-2 Clinical Trial Progress in Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

Immix Biopharma Inc. Conducted Annual Stockholders Meeting

Gabriel Morris, CFO of Immix Biopharma Inc., Reports Acquisition of Common Shares

Ilya Rachman, CEO and Chairman, Reports Acquisition of Common Shares in Immix Biopharma Inc

Immix Biopharma Inc. Unveils Innovative Cell Therapy Platform for AL Amyloidosis and Other Serious Diseases

Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Immix Biopharma: Files for Offering of up to $13.5 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS

Immix Biopharma announces NXC-201 trial met primary endpoint

Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales

Immix Biopharma Announces Primary Endpoint Met in Positive Nxc-201 Interim Results Presented at Asco, Enabling Path to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

BRIEF-Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial

Immix Biopharma Inc: Anticipate Completing Nexicart-2 Clinical Trial Ahead of Schedule

THOMSON REUTERS

Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2

THOMSON REUTERS

Immix Biopharma Announces Positive Results for Nxc-201 at Asco Oral Presentation, Enabling Pathway to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS

Immix Biopharma Inc. Files Amendment to 10-K Annual Report

Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IMMX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":2.65,"timestamp":1752264000000,"preClose":2.71,"halted":0,"volume":286916,"hourTrading":{"tag":"盘后","latestPrice":2.65,"preClose":2.65,"latestTime":"16:43 EDT","volume":101,"amount":264.34,"timestamp":1752266633564},"delay":0,"floatShares":18062555,"shares":27852341,"eps":-0.700031,"marketStatus":"Market Closed","change":-0.06,"latestTime":"07-11 16:00:00 EDT","open":2.7,"high":2.74,"low":2.61,"amount":769854.4457800001,"amplitude":0.04797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.700031,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":2.71,"preHourTrading":{"tag":"盘前","latestPrice":2.67,"preClose":2.71,"latestTime":"08:45 EDT","volume":220,"amount":589.40002,"timestamp":1752237916897},"postHourTrading":{"tag":"盘后","latestPrice":2.65,"preClose":2.65,"latestTime":"16:43 EDT","volume":101,"amount":264.34,"timestamp":1752266633564},"volumeRatio":1.767116,"impliedVol":1.7939,"impliedVolPercentile":0.996},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMMX\",,,,,undefined,":{"symbol":"IMMX","floatShares":18062555,"roa":"-50.17%","roe":"-112.34%","lyrEps":-0.764111,"volumeRatio":1.767116,"shares":27852341,"dividePrice":0,"high":2.74,"amplitude":0.04797,"preClose":2.71,"low":2.61,"week52Low":1.26,"pbRate":"7.69","week52High":3,"institutionHeld":0,"latestPrice":2.65,"eps":-0.700031,"divideRate":0,"volume":286916,"delay":0,"ttmEps":-0.700031,"open":2.7,"prevYearClose":2.2,"prevWeekClose":2.55,"prevMonthClose":2.07,"prevQuarterClose":2.07,"fiveDayClose":2.55,"twentyDayClose":2.43,"sixtyDayClose":1.63},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMMX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550782959","title":"Immix Biopharma announces ‘class-leading’ safety profile for NXC-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2550782959","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550782959?lang=en_us&edition=fundamental","pubTime":"2025-07-11 21:40","pubTimestamp":1752241251,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced a “class-leading” safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-class-leading-safety-profile-for-nxc-201-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-class-leading-safety-profile-for-nxc-201-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","BK4139","NXC","IMMX","BK4022","CAR"],"gpt_icon":0},{"id":"2550595999","title":"Immix Biopharma Accelerates Toward BLA Submission for NEXICART-2, Paving Way for FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2550595999","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550595999?lang=en_us&edition=fundamental","pubTime":"2025-07-11 21:36","pubTimestamp":1752240973,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on July 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDL7Cff1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IMMX","LU2210149790.SGD","BK4588","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD"],"gpt_icon":0},{"id":"2549530198","title":"Immix Biopharma Expands NEXICART-2 Clinical Trial Footprint, Accelerating Path to FDA Approval for Novel Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2549530198","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549530198?lang=en_us&edition=fundamental","pubTime":"2025-07-07 21:35","pubTimestamp":1751895317,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on July 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDLbgQWpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IMMX"],"gpt_icon":0},{"id":"2549530118","title":"Immix Biopharma Announces Accelerated Nexicart-2 Clinical Trial Progress in Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2549530118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549530118?lang=en_us&edition=fundamental","pubTime":"2025-07-07 21:35","pubTimestamp":1751895300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nTUA1QBMN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2545219440","title":"Immix Biopharma Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2545219440","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545219440?lang=en_us&edition=fundamental","pubTime":"2025-06-24 05:02","pubTimestamp":1750712548,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. held its Annual Meeting of stockholders on June 20, 2025. During the meeting, stockholders elected Ilya Rachman, Gabriel Morris, Jason Hsu, Magda Marquet, and Helen C. Adams as directors of the company. Additionally, the appointment of Crowe LLP as the company's independent registered public accounting firm for the year ending December 31, 2025, was ratified. Both proposals were approved by the stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2025, and is solely responsible for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL3rBxcm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2544042120","title":"Gabriel Morris, CFO of Immix Biopharma Inc., Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2544042120","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544042120?lang=en_us&edition=fundamental","pubTime":"2025-06-20 21:36","pubTimestamp":1750426568,"startTime":"0","endTime":"0","summary":"Gabriel S. Morris, CFO and Director of Immix Biopharma Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL4JQh6Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Gabriel Morris, CFO of Immix Biopharma Inc., Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2544120040","title":"Ilya Rachman, CEO and Chairman, Reports Acquisition of Common Shares in Immix Biopharma Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2544120040","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544120040?lang=en_us&edition=fundamental","pubTime":"2025-06-20 21:36","pubTimestamp":1750426567,"startTime":"0","endTime":"0","summary":"Ilya Rachman, CEO and Chairman of Immix Biopharma Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL7z53rC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2541941670","title":"Immix Biopharma Inc. Unveils Innovative Cell Therapy Platform for AL Amyloidosis and Other Serious Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2541941670","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541941670?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:06","pubTimestamp":1749074782,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL8CZcD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2540417068","title":"Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2540417068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540417068?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:28","pubTimestamp":1749036480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 04, 2025 07:28 ET (11:28 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2540701160","title":"Immix Biopharma: Files for Offering of up to $13.5 Mln Shares of Common Stock -  SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701160","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701160?lang=en_us&edition=fundamental","pubTime":"2025-06-04 03:10","pubTimestamp":1748977835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2540701454","title":"Immix Biopharma announces NXC-201 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701454","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701454?lang=en_us&edition=fundamental","pubTime":"2025-06-04 03:10","pubTimestamp":1748977819,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced meeting its primary endpoint of complete response rate for cell therapy NXC-201 at an oral presentation of interim...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-nxc-201-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-announces-nxc-201-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139","NXC"],"gpt_icon":0},{"id":"2540701969","title":"Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701969","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701969?lang=en_us&edition=fundamental","pubTime":"2025-06-04 03:01","pubTimestamp":1748977277,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC, allowing the company to offer and sell shares of its common stock at its discretion through the agent. The sales will be conducted under the company's effective Registration Statement on Form S-3. The agent will earn a commission of 3% on the gross sales proceeds and will also be reimbursed for certain specified expenses up to $50,000. The agreement enables Immix Biopharma to strategically sell shares in alignment with market conditions and company requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL4ngqwL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immix Biopharma Inc. Announces At The Market Offering Agreement for Common Stock Sales","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0},{"id":"2540701618","title":"Immix Biopharma Announces Primary Endpoint Met in Positive Nxc-201 Interim Results Presented at Asco, Enabling Path to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540701618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540701618?lang=en_us&edition=fundamental","pubTime":"2025-06-04 02:55","pubTimestamp":1748976900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA9NRT1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2537213178","title":"BRIEF-Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2537213178","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537213178?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:13","pubTimestamp":1748006003,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2May 23 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA FURTHER EXPANDS U.S. CLIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV02J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2537134691","title":"Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2537134691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537134691?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:10","pubTimestamp":1748005819,"startTime":"0","endTime":"0","summary":"Immix Biopharma (IMMX) announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-expands-u-s-clinical-sites-for-nexicart-2-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-expands-u-s-clinical-sites-for-nexicart-2-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2537485131","title":"Immix Biopharma Inc: Anticipate Completing Nexicart-2 Clinical Trial Ahead of Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2537485131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537485131?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:05","pubTimestamp":1748005508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV02J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2537131940","title":"Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2537131940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537131940?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:05","pubTimestamp":1748005500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUARQHPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2537432924","title":"Immix Biopharma Announces Positive Results for Nxc-201 at Asco Oral Presentation, Enabling Pathway to Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2537432924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537432924?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA3YRMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2536560658","title":"Immix Biopharma Inc. Files Amendment to 10-K Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2536560658","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536560658?lang=en_us&edition=fundamental","pubTime":"2025-05-20 05:20","pubTimestamp":1747689607,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. filed an amendment to the 10-K annual report for the fiscal year ended December 31, 2024. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLc3Z1vY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2533562064","title":"Immix Biopharma Inc  expected to post a loss of 23 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533562064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533562064?lang=en_us&edition=fundamental","pubTime":"2025-05-06 06:48","pubTimestamp":1746485285,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc  expected to post a loss of23cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report resultson May 7 (estimated) for the period ending March 31 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD35P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"IMMX","fiscalQuarterEnding":"2025/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-24","symbol":"IMMX","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2024-11-12","symbol":"IMMX","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-08-12","symbol":"IMMX","fiscalQuarterEnding":"2024/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-05-09","symbol":"IMMX","fiscalQuarterEnding":"2024/03","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMMX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1719892800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMMX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMMX","date":"2025-07-10","current":-3.665323,"percent":0.295742,"low":-37.240428,"twenty":-5.205796,"median":-2.788887,"eighty":-1.213721,"high":-0.384227,"avg":-4.350102,"sd":5.551197,"marketCap":76593937},"quantilePoints":[{"date":"2021-12-17","current":-22.068402,"twenty":-20.976016,"median":-17.642249,"eighty":-15.03674,"marketCap":52834756},{"date":"2021-12-23","current":-16.275446,"twenty":-19.828459,"median":-17.958163,"eighty":-15.532222,"marketCap":38965632},{"date":"2021-12-31","current":-19.640878,"twenty":-19.806391,"median":-18.096089,"eighty":-16.937498,"marketCap":47022932},{"date":"2022-01-07","current":-29.461317,"twenty":-29.957856,"median":-19.420194,"eighty":-17.952645,"marketCap":70534399},{"date":"2022-01-14","current":-32.219867,"twenty":-32.197799,"median":-20.247759,"eighty":-17.985748,"marketCap":77138743},{"date":"2022-01-21","current":-24.882123,"twenty":-32.142628,"median":-24.882123,"eighty":-18.007816,"marketCap":59571187},{"date":"2022-01-28","current":-21.461521,"twenty":-32.021251,"median":-22.399428,"eighty":-18.140226,"marketCap":51381800},{"date":"2022-02-04","current":-24.109729,"twenty":-31.756431,"median":-22.399428,"eighty":-18.493321,"marketCap":57721970},{"date":"2022-02-11","current":-23.282164,"twenty":-31.039208,"median":-23.30975,"eighty":-19.276749,"marketCap":55740667},{"date":"2022-02-18","current":-19.75122,"twenty":-30.222677,"median":-22.399428,"eighty":-19.59674,"marketCap":47287106},{"date":"2022-02-25","current":-17.654721,"twenty":-29.957856,"median":-22.123573,"eighty":-18.096089,"marketCap":42267804},{"date":"2022-03-04","current":-11.641082,"twenty":-29.902685,"median":-21.875304,"eighty":-17.875406,"marketCap":27870333},{"date":"2022-03-11","current":-10.261807,"twenty":-29.461317,"median":-21.461521,"eighty":-16.440959,"marketCap":24568161},{"date":"2022-03-18","current":-13.296212,"twenty":-27.199305,"median":-20.771884,"eighty":-15.03674,"marketCap":31832940},{"date":"2022-03-25","current":-11.751424,"twenty":-26.592424,"median":-19.75122,"eighty":-13.241041,"marketCap":28134507},{"date":"2022-04-01","current":-1.409519,"twenty":-26.482082,"median":-19.392608,"eighty":-11.751424,"marketCap":34369548},{"date":"2022-04-08","current":-1.028722,"twenty":-25.433833,"median":-18.096089,"eighty":-11.254885,"marketCap":25084227},{"date":"2022-04-14","current":-1.023038,"twenty":-24.992465,"median":-17.985748,"eighty":-10.416286,"marketCap":24945640},{"date":"2022-04-22","current":-0.818431,"twenty":-24.264208,"median":-17.765064,"eighty":-1.459534,"marketCap":19956512},{"date":"2022-04-29","current":-0.785819,"twenty":-24.109729,"median":-17.047841,"eighty":-1.310625,"marketCap":19161305},{"date":"2022-05-06","current":-0.848456,"twenty":-23.491814,"median":-15.778907,"eighty":-1.093514,"marketCap":20688655},{"date":"2022-05-13","current":-0.733622,"twenty":-23.293198,"median":-15.03674,"eighty":-0.9878,"marketCap":18119930},{"date":"2022-05-20","current":-1.191784,"twenty":-22.840796,"median":-13.351383,"eighty":-0.962793,"marketCap":29436208},{"date":"2022-05-27","current":-1.506595,"twenty":-22.465633,"median":-12.854844,"eighty":-0.975297,"marketCap":37211810},{"date":"2022-06-03","current":-1.394163,"twenty":-22.30012,"median":-12.247963,"eighty":-0.98098,"marketCap":34434809},{"date":"2022-06-10","current":-1.366055,"twenty":-22.16771,"median":-11.696253,"eighty":-0.986663,"marketCap":33740559},{"date":"2022-06-17","current":-1.366055,"twenty":-22.09047,"median":-11.254885,"eighty":-1.009398,"marketCap":33740559},{"date":"2022-06-24","current":-1.197406,"twenty":-22.046334,"median":-10.482491,"eighty":-1.025312,"marketCap":29575058},{"date":"2022-07-01","current":-1.461622,"twenty":-21.902889,"median":-10.344563,"eighty":-1.033234,"marketCap":36101010},{"date":"2022-07-08","current":-1.506595,"twenty":-21.737376,"median":-5.965715,"eighty":-1.047976,"marketCap":37211810},{"date":"2022-07-15","current":-1.534704,"twenty":-21.682205,"median":-1.669623,"eighty":-1.083284,"marketCap":37906060},{"date":"2022-07-22","current":-1.377298,"twenty":-21.461521,"median":-1.540325,"eighty":-1.107154,"marketCap":34018259},{"date":"2022-07-29","current":-1.371676,"twenty":-21.428418,"median":-1.529082,"eighty":-1.149213,"marketCap":33879409},{"date":"2022-08-05","current":-1.414851,"twenty":-21.086358,"median":-1.509406,"eighty":-1.161365,"marketCap":34945778},{"date":"2022-08-12","current":-1.308074,"twenty":-20.181554,"median":-1.484109,"eighty":-1.191784,"marketCap":34079789},{"date":"2022-08-19","current":-1.073155,"twenty":-19.88363,"median":-1.475262,"eighty":-1.182306,"marketCap":27959337},{"date":"2022-08-26","current":-1.09985,"twenty":-19.729152,"median":-1.461622,"eighty":-1.149213,"marketCap":28654843},{"date":"2022-09-02","current":-1.035781,"twenty":-19.629844,"median":-1.425082,"eighty":-1.094994,"marketCap":26985628},{"date":"2022-09-09","current":-0.961034,"twenty":-19.585706,"median":-1.416649,"eighty":-1.051798,"marketCap":25038212},{"date":"2022-09-16","current":-0.977051,"twenty":-19.19951,"median":-1.413839,"eighty":-1.023038,"marketCap":25455515},{"date":"2022-09-23","current":-0.787514,"twenty":-18.316774,"median":-1.407462,"eighty":-0.983253,"marketCap":20517424},{"date":"2022-09-30","current":-0.726114,"twenty":-18.096089,"median":-1.388541,"eighty":-0.966203,"marketCap":18917760},{"date":"2022-10-07","current":-0.69408,"twenty":-17.985748,"median":-1.380109,"eighty":-0.928999,"marketCap":18083153},{"date":"2022-10-14","current":-0.646028,"twenty":-17.985748,"median":-1.371676,"eighty":-0.916325,"marketCap":16831242},{"date":"2022-10-21","current":-0.630011,"twenty":-17.930577,"median":-1.366055,"eighty":-0.871234,"marketCap":16413939},{"date":"2022-10-28","current":-0.573951,"twenty":-17.875406,"median":-1.366055,"eighty":-0.854252,"marketCap":14953376},{"date":"2022-11-04","current":-0.485856,"twenty":-17.654721,"median":-1.352001,"eighty":-0.819985,"marketCap":12658207},{"date":"2022-11-11","current":-0.448265,"twenty":-17.213353,"median":-1.343568,"eighty":-0.800862,"marketCap":12186169},{"date":"2022-11-18","current":-0.665994,"twenty":-17.047841,"median":-1.333979,"eighty":-0.785819,"marketCap":18105187},{"date":"2022-11-25","current":-0.686486,"twenty":-16.562335,"median":-1.321082,"eighty":-0.77203,"marketCap":18662269},{"date":"2022-12-02","current":-0.588739,"twenty":-16.308549,"median":-1.309839,"eighty":-0.750858,"marketCap":16004985},{"date":"2022-12-09","current":-0.712102,"twenty":-15.480984,"median":-1.267676,"eighty":-0.736159,"marketCap":19358623},{"date":"2022-12-16","current":-0.968253,"twenty":-15.085866,"median":-1.244005,"eighty":-0.741064,"marketCap":26322156},{"date":"2022-12-23","current":-1.111698,"twenty":-15.03674,"median":-1.214271,"eighty":-0.746567,"marketCap":30221735},{"date":"2022-12-30","current":-1.173175,"twenty":-14.853091,"median":-1.211283,"eighty":-0.747676,"marketCap":31892983},{"date":"2023-01-06","current":-1.19879,"twenty":-14.201016,"median":-1.209622,"eighty":-0.747791,"marketCap":32589336},{"date":"2023-01-13","current":-1.127067,"twenty":-13.362417,"median":-1.203028,"eighty":-0.749439,"marketCap":30639547},{"date":"2023-01-20","current":-1.101452,"twenty":-13.285178,"median":-1.197406,"eighty":-0.751884,"marketCap":29943194},{"date":"2023-01-27","current":-1.229528,"twenty":-13.163802,"median":-1.200909,"eighty":-0.753717,"marketCap":33424960},{"date":"2023-02-03","current":-1.608632,"twenty":-12.744502,"median":-1.208649,"eighty":-0.758575,"marketCap":43730990},{"date":"2023-02-10","current":-1.357604,"twenty":-12.2921,"median":-1.211283,"eighty":-0.764481,"marketCap":36906727},{"date":"2023-02-17","current":-1.173175,"twenty":-12.148655,"median":-1.210595,"eighty":-0.769597,"marketCap":31892983},{"date":"2023-02-24","current":-1.101452,"twenty":-11.751424,"median":-1.203913,"eighty":-0.774166,"marketCap":29943194},{"date":"2023-03-03","current":-1.075837,"twenty":-11.751424,"median":-1.198098,"eighty":-0.77443,"marketCap":29246840},{"date":"2023-03-10","current":-0.922146,"twenty":-11.641082,"median":-1.191784,"eighty":-0.785819,"marketCap":25068720},{"date":"2023-03-17","current":-0.932392,"twenty":-11.365227,"median":-1.185983,"eighty":-0.785819,"marketCap":25347261},{"date":"2023-03-24","current":-0.935614,"twenty":-11.254885,"median":-1.179936,"eighty":-0.787514,"marketCap":25434844},{"date":"2023-03-31","current":-3.073723,"twenty":-10.915583,"median":-1.185983,"eighty":-0.791513,"marketCap":25295856},{"date":"2023-04-06","current":-2.938614,"twenty":-10.569109,"median":-1.191784,"eighty":-0.796068,"marketCap":24183950},{"date":"2023-04-14","current":-2.98928,"twenty":-10.438354,"median":-1.197406,"eighty":-0.800131,"marketCap":24600914},{"date":"2023-04-21","current":-3.175054,"twenty":-10.383183,"median":-1.20347,"eighty":-0.807049,"marketCap":26129785},{"date":"2023-04-28","current":-3.884375,"twenty":-10.328012,"median":-1.210595,"eighty":-0.808596,"marketCap":31967290},{"date":"2023-05-05","current":-4.576322,"twenty":-10.272841,"median":-1.214215,"eighty":-0.816464,"marketCap":37661819},{"date":"2023-05-11","current":-3.813602,"twenty":-7.053908,"median":-1.216776,"eighty":-0.819363,"marketCap":31384849},{"date":"2023-05-19","current":-2.841134,"twenty":-4.874631,"median":-1.234651,"eighty":-0.836103,"marketCap":26642250},{"date":"2023-05-26","current":-2.380008,"twenty":-4.766155,"median":-1.244451,"eighty":-0.847813,"marketCap":22318115},{"date":"2023-06-02","current":-3.190234,"twenty":-4.657679,"median":-1.251483,"eighty":-0.848456,"marketCap":29915874},{"date":"2023-06-09","current":-3.254359,"twenty":-4.562763,"median":-1.270512,"eighty":-0.850774,"marketCap":30517199},{"date":"2023-06-16","current":-3.783393,"twenty":-4.400049,"median":-1.307224,"eighty":-0.856388,"marketCap":35478123},{"date":"2023-06-23","current":-4.10402,"twenty":-4.223113,"median":-1.309839,"eighty":-0.860781,"marketCap":38484743},{"date":"2023-06-30","current":-4.376552,"twenty":-4.23227,"median":-1.321082,"eighty":-0.865539,"marketCap":41040371},{"date":"2023-07-07","current":-4.152114,"twenty":-4.486677,"median":-1.332157,"eighty":-0.869324,"marketCap":38935736},{"date":"2023-07-14","current":-3.735299,"twenty":-4.39579,"median":-1.337947,"eighty":-0.871041,"marketCap":35027129},{"date":"2023-07-21","current":-3.572376,"twenty":-4.261126,"median":-1.345284,"eighty":-0.89609,"marketCap":33499345},{"date":"2023-07-28","current":-3.503009,"twenty":-4.195644,"median":-1.34919,"eighty":-0.905882,"marketCap":32848872},{"date":"2023-08-04","current":-3.503009,"twenty":-4.184638,"median":-1.356208,"eighty":-0.90747,"marketCap":32848872},{"date":"2023-08-11","current":-3.29491,"twenty":-4.158526,"median":-1.366055,"eighty":-0.911914,"marketCap":30897454},{"date":"2023-08-18","current":-2.330617,"twenty":-4.113639,"median":-1.367895,"eighty":-0.915656,"marketCap":26547513},{"date":"2023-08-25","current":-2.916846,"twenty":-4.034399,"median":-1.377298,"eighty":-0.920982,"marketCap":33225108},{"date":"2023-09-01","current":-2.902547,"twenty":-3.980385,"median":-1.38292,"eighty":-0.922146,"marketCap":33062240},{"date":"2023-09-08","current":-3.560267,"twenty":-3.968181,"median":-1.391352,"eighty":-0.923054,"marketCap":40554176},{"date":"2023-09-15","current":-3.631759,"twenty":-3.972707,"median":-1.409519,"eighty":-0.92366,"marketCap":41368517},{"date":"2023-09-22","current":-4.932901,"twenty":-4.034479,"median":-1.414345,"eighty":-0.926863,"marketCap":56189522},{"date":"2023-09-29","current":-6.358344,"twenty":-4.1851,"median":-1.416649,"eighty":-0.928999,"marketCap":72426414},{"date":"2023-10-06","current":-6.479291,"twenty":-4.315729,"median":-1.429506,"eighty":-0.931035,"marketCap":73804091},{"date":"2023-10-13","current":-5.615385,"twenty":-4.616006,"median":-1.461622,"eighty":-0.934325,"marketCap":63963545},{"date":"2023-10-20","current":-4.872427,"twenty":-4.777335,"median":-1.471175,"eighty":-0.943737,"marketCap":55500676},{"date":"2023-10-27","current":-6.375622,"twenty":-4.847512,"median":-1.475262,"eighty":-0.949152,"marketCap":72623225},{"date":"2023-11-03","current":-6.064616,"twenty":-4.932901,"median":-1.484109,"eighty":-0.950356,"marketCap":69080629},{"date":"2023-11-10","current":-6.410178,"twenty":-5.131598,"median":-1.509406,"eighty":-0.958007,"marketCap":73016847},{"date":"2023-11-17","current":-6.195423,"twenty":-5.719054,"median":-1.529082,"eighty":-0.961034,"marketCap":87580854},{"date":"2023-11-24","current":-6.703742,"twenty":-5.892712,"median":-1.540325,"eighty":-0.965169,"marketCap":94766658},{"date":"2023-12-01","current":-7.181577,"twenty":-6.076855,"median":-1.603509,"eighty":-0.967843,"marketCap":101521514},{"date":"2023-12-08","current":-7.01293,"twenty":-6.195898,"median":-1.669623,"eighty":-0.968253,"marketCap":99137447},{"date":"2023-12-15","current":-7.982654,"twenty":-6.218411,"median":-2.022607,"eighty":-0.97102,"marketCap":112845832},{"date":"2023-12-22","current":-10.034533,"twenty":-6.379078,"median":-2.409758,"eighty":-0.973043,"marketCap":141851979},{"date":"2023-12-29","current":-9.430212,"twenty":-6.451646,"median":-2.432071,"eighty":-0.974846,"marketCap":133309073},{"date":"2024-01-05","current":-8.50265,"twenty":-6.565681,"median":-2.473599,"eighty":-0.977051,"marketCap":120196705},{"date":"2024-01-12","current":-8.685352,"twenty":-6.703742,"median":-2.585988,"eighty":-0.97757,"marketCap":122779444},{"date":"2024-01-19","current":-7.518873,"twenty":-6.911741,"median":-2.60785,"eighty":-0.978313,"marketCap":106289648},{"date":"2024-01-26","current":-5.256184,"twenty":-7.018552,"median":-2.655395,"eighty":-0.982302,"marketCap":74303417},{"date":"2024-02-02","current":-5.466993,"twenty":-6.911741,"median":-2.795833,"eighty":-0.986834,"marketCap":77283501},{"date":"2024-02-09","current":-5.804128,"twenty":-6.774012,"median":-2.816758,"eighty":-0.987729,"marketCap":82049361},{"date":"2024-02-16","current":-5.229106,"twenty":-6.712174,"median":-2.843244,"eighty":-0.988695,"marketCap":73920631},{"date":"2024-02-23","current":-5.498647,"twenty":-6.703742,"median":-2.873951,"eighty":-0.994969,"marketCap":77730973},{"date":"2024-03-01","current":-6.019761,"twenty":-6.693474,"median":-2.904837,"eighty":-1.003911,"marketCap":85097634},{"date":"2024-03-08","current":-6.073669,"twenty":-6.663866,"median":-2.910842,"eighty":-1.008419,"marketCap":85859703},{"date":"2024-03-15","current":-5.10332,"twenty":-6.640353,"median":-2.938614,"eighty":-1.009238,"marketCap":72142472},{"date":"2024-03-22","current":-5.462708,"twenty":-6.634794,"median":-2.972392,"eighty":-1.015386,"marketCap":77222928},{"date":"2024-03-28","current":-5.516617,"twenty":-6.623022,"median":-3.014613,"eighty":-1.020906,"marketCap":77984996},{"date":"2024-04-05","current":-4.808357,"twenty":-6.594122,"median":-3.042817,"eighty":-1.023666,"marketCap":74173940},{"date":"2024-04-12","current":-4.945249,"twenty":-6.572627,"median":-3.073723,"eighty":-1.026253,"marketCap":76285653},{"date":"2024-04-19","current":-3.781661,"twenty":-6.536582,"median":-3.124388,"eighty":-1.031174,"marketCap":58336088},{"date":"2024-04-26","current":-3.593434,"twenty":-6.487476,"median":-3.158168,"eighty":-1.035224,"marketCap":55432482},{"date":"2024-05-03","current":-3.953922,"twenty":-6.475173,"median":-3.175054,"eighty":-1.037469,"marketCap":60993385},{"date":"2024-05-10","current":-3.731407,"twenty":-6.445469,"median":-3.190234,"eighty":-1.04472,"marketCap":57560857},{"date":"2024-05-17","current":-3.263275,"twenty":-6.403267,"median":-3.190234,"eighty":-1.053237,"marketCap":59409141},{"date":"2024-05-24","current":-3.07473,"twenty":-6.385989,"median":-3.190496,"eighty":-1.057425,"marketCap":55976613},{"date":"2024-05-31","current":-3.03122,"twenty":-6.372166,"median":-3.190496,"eighty":-1.060468,"marketCap":55184491},{"date":"2024-06-07","current":-2.988868,"twenty":-6.351433,"median":-3.175054,"eighty":-1.060468,"marketCap":54413458},{"date":"2024-06-14","current":-3.017886,"twenty":-6.323788,"median":-3.168385,"eighty":-1.060468,"marketCap":54941744},{"date":"2024-06-21","current":-2.785741,"twenty":-6.296199,"median":-3.161751,"eighty":-1.064566,"marketCap":50715456},{"date":"2024-06-28","current":-3.090431,"twenty":-6.282377,"median":-3.158171,"eighty":-1.065591,"marketCap":56262459},{"date":"2024-07-05","current":-3.554721,"twenty":-6.254675,"median":-3.158171,"eighty":-1.065591,"marketCap":64715035},{"date":"2024-07-12","current":-2.916322,"twenty":-6.209345,"median":-3.158168,"eighty":-1.070714,"marketCap":53092743},{"date":"2024-07-15","current":-3.061413,"twenty":-6.207036,"median":-3.158166,"eighty":-1.071202,"marketCap":55734173},{"date":"2024-08-02","current":-3.017886,"twenty":-6.204727,"median":-3.149722,"eighty":-1.07169,"marketCap":54941744},{"date":"2024-08-09","current":-2.901813,"twenty":-6.196849,"median":-3.133958,"eighty":-1.074228,"marketCap":52828600},{"date":"2024-08-16","current":-2.727429,"twenty":-6.184568,"median":-3.121919,"eighty":-1.075837,"marketCap":51881405},{"date":"2024-08-23","current":-3.189215,"twenty":-6.151983,"median":-3.124388,"eighty":-1.077452,"marketCap":60665558},{"date":"2024-08-30","current":-3.059338,"twenty":-6.126842,"median":-3.121919,"eighty":-1.082358,"marketCap":58195015},{"date":"2024-09-06","current":-3.030476,"twenty":-6.115383,"median":-3.11765,"eighty":-1.08762,"marketCap":57646005},{"date":"2024-09-13","current":-2.616311,"twenty":-6.073669,"median":-3.10494,"eighty":-1.093836,"marketCap":49767718},{"date":"2024-09-20","current":-2.554258,"twenty":-6.071858,"median":-3.096621,"eighty":-1.094187,"marketCap":48587347},{"date":"2024-09-27","current":-2.294503,"twenty":-6.055645,"median":-3.0882,"eighty":-1.094875,"marketCap":43646261},{"date":"2024-10-04","current":-1.933732,"twenty":-6.018828,"median":-3.074226,"eighty":-1.096448,"marketCap":36783641},{"date":"2024-10-11","current":-1.991456,"twenty":-6.007724,"median":-3.06426,"eighty":-1.097509,"marketCap":37881661},{"date":"2024-10-18","current":-2.438812,"twenty":-5.972157,"median":-3.060376,"eighty":-1.10017,"marketCap":46391309},{"date":"2024-10-25","current":-2.294503,"twenty":-5.941702,"median":-3.03122,"eighty":-1.101452,"marketCap":43646261},{"date":"2024-10-31","current":-2.381088,"twenty":-5.916977,"median":-3.023057,"eighty":-1.101452,"marketCap":45293290},{"date":"2024-11-08","current":-2.525397,"twenty":-5.911944,"median":-3.017886,"eighty":-1.101452,"marketCap":48038338},{"date":"2024-11-15","current":-2.035664,"twenty":-5.909113,"median":-3.016045,"eighty":-1.101452,"marketCap":44562371},{"date":"2024-11-22","current":-2.111059,"twenty":-5.888612,"median":-2.996328,"eighty":-1.106575,"marketCap":46212830},{"date":"2024-11-29","current":-2.65139,"twenty":-5.866126,"median":-2.988868,"eighty":-1.110673,"marketCap":58041114},{"date":"2024-12-06","current":-3.166589,"twenty":-5.85853,"median":-2.974359,"eighty":-1.111698,"marketCap":69319245},{"date":"2024-12-13","current":-2.676521,"twenty":-5.85743,"median":-2.967105,"eighty":-1.123993,"marketCap":58591266},{"date":"2024-12-20","current":-2.789614,"twenty":-5.829133,"median":-2.955503,"eighty":-1.127067,"marketCap":61066954},{"date":"2024-12-27","current":-2.638824,"twenty":-5.811316,"median":-2.943891,"eighty":-1.127067,"marketCap":57766037},{"date":"2025-01-03","current":-2.764482,"twenty":-5.804128,"median":-2.938614,"eighty":-1.127067,"marketCap":60516801},{"date":"2025-01-10","current":-2.827311,"twenty":-5.790569,"median":-2.938614,"eighty":-1.129098,"marketCap":61892183},{"date":"2025-01-17","current":-2.588561,"twenty":-5.735516,"median":-2.916584,"eighty":-1.137241,"marketCap":56665732},{"date":"2025-01-24","current":-2.575995,"twenty":-5.73225,"median":-2.915797,"eighty":-1.137313,"marketCap":56390655},{"date":"2025-01-31","current":-2.475468,"twenty":-5.73225,"median":-2.904837,"eighty":-1.137313,"marketCap":54190044},{"date":"2025-02-07","current":-2.538297,"twenty":-5.719054,"median":-2.903771,"eighty":-1.147559,"marketCap":55565426},{"date":"2025-02-14","current":-2.5006,"twenty":-5.615385,"median":-2.901813,"eighty":-1.148076,"marketCap":54740197},{"date":"2025-02-21","current":-2.236717,"twenty":-5.579497,"median":-2.888249,"eighty":-1.152623,"marketCap":48963593},{"date":"2025-02-28","current":-1.985401,"twenty":-5.541774,"median":-2.868902,"eighty":-1.165176,"marketCap":43462066},{"date":"2025-03-07","current":-2.073362,"twenty":-5.534586,"median":-2.845354,"eighty":-1.172146,"marketCap":45387601},{"date":"2025-03-14","current":-1.985401,"twenty":-5.520211,"median":-2.842004,"eighty":-1.173175,"marketCap":43462066},{"date":"2025-03-21","current":-2.286981,"twenty":-5.502241,"median":-2.829268,"eighty":-1.174313,"marketCap":50063899},{"date":"2025-03-28","current":-2.193309,"twenty":-5.498647,"median":-2.816758,"eighty":-1.178868,"marketCap":47404804},{"date":"2025-04-04","current":-2.026566,"twenty":-5.473324,"median":-2.814746,"eighty":-1.182724,"marketCap":43800930},{"date":"2025-04-11","current":-1.876497,"twenty":-5.463565,"median":-2.796559,"eighty":-1.183421,"marketCap":40557444},{"date":"2025-04-17","current":-2.01374,"twenty":-5.462708,"median":-2.786951,"eighty":-1.186495,"marketCap":43523709},{"date":"2025-04-25","current":-2.244614,"twenty":-5.451927,"median":-2.764482,"eighty":-1.190488,"marketCap":48513689},{"date":"2025-05-02","current":-2.616579,"twenty":-5.433958,"median":-2.746872,"eighty":-1.191784,"marketCap":56553100},{"date":"2025-05-09","current":-2.751256,"twenty":-5.40031,"median":-2.741859,"eighty":-1.192914,"marketCap":59463921},{"date":"2025-05-16","current":-2.77262,"twenty":-5.376785,"median":-2.741859,"eighty":-1.19591,"marketCap":57939205},{"date":"2025-05-23","current":-3.215034,"twenty":-5.372861,"median":-2.751256,"eighty":-1.198236,"marketCap":67184276},{"date":"2025-05-30","current":-3.001587,"twenty":-5.371163,"median":-2.741859,"eighty":-1.200485,"marketCap":62723909},{"date":"2025-06-06","current":-2.921545,"twenty":-5.340508,"median":-2.75157,"eighty":-1.203382,"marketCap":61051271},{"date":"2025-06-13","current":-3.321757,"twenty":-5.292213,"median":-2.764482,"eighty":-1.205807,"marketCap":69414459},{"date":"2025-06-20","current":-3.185499,"twenty":-5.277648,"median":-2.77262,"eighty":-1.209038,"marketCap":66567094},{"date":"2025-06-27","current":-2.985572,"twenty":-5.250768,"median":-2.77262,"eighty":-1.21087,"marketCap":62389243},{"date":"2025-07-03","current":-3.398754,"twenty":-5.229106,"median":-2.77918,"eighty":-1.211971,"marketCap":71023469},{"date":"2025-07-10","current":-3.665323,"twenty":-5.205796,"median":-2.788887,"eighty":-1.213721,"marketCap":76593937}],"updateTime":1752293647756}}}